{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:41:34Z","timestamp":1790635294472,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The purpose of this study was to evaluate choroidal vascular changes in patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept injection over a 3-month period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enhanced depth imaging optical coherence tomography scans of 60 eyes with treatment-na\u00efve nAMD and 60 unaffected fellow eyes were retrospectively analyzed. Data was collected at baseline and after 3 monthly intravitreal injections of aflibercept. The ImageJ software was used to binarize OCT scans and measure total choroid area (TCA), luminal area (LA), and stromal area (SA). Choroidal vascularity index (CVI) was defined as the ratio of LA to TCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After treatment, subfoveal choroidal thickness (CT) in nAMD eyes significantly decreased from 210. 6 \u00b1 61.6 to 194.6 \u00b1 58.7 \u03bcm (<jats:italic>P<\/jats:italic> &lt; 0.001), TCA from 1.620 \u00b1 0.502 to 1.500 \u00b1 0.451 mm<jats:sup>2<\/jats:sup> (<jats:italic>P<\/jats:italic> &lt; 0.001), LA from 1.075 \u00b1 0.335 to 0.985 \u00b1 0.307 mm<jats:sup>2<\/jats:sup> (<jats:italic>P<\/jats:italic> &lt; 0.001), SA from 0.545 \u00b1 0.176 to 0.516 \u00b1 0.153 mm<jats:sup>2<\/jats:sup> (<jats:italic>P<\/jats:italic> = 0.005), and CVI from 66.36 \u00b1 2.89 to 65.46 \u00b1 2.87% (<jats:italic>P<\/jats:italic> = 0.009). The decrease of CVI after treatment was significantly correlated with baseline CVI (Rs = 0.466, <jats:italic>P<\/jats:italic> &lt; 0.001), but not with the change in BCVA and presence of dry macula after treatment (always <jats:italic>P<\/jats:italic> &gt; 0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Choroidal thickness and vascularity significantly decreased after treatment with aflibercept in nAMD eyes. Besides the pharmacologic effect on the neovascular lesion, aflibercept may induce vascular changes also on the underlying choroid.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-020-04957-5","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T04:02:42Z","timestamp":1602561762000},"page":"911-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-6941","authenticated-orcid":false,"given":"Marco","family":"Pellegrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bernabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mercanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Peiretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giamberto","family":"Casini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Loiudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"4957_CR1","doi-asserted-by":"publisher","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"4957_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"4957_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","volume":"85","author":"J Lowe","year":"2007","unstructured":"Lowe J, Araujo J, Yang J et al (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425\u2013430. https:\/\/doi.org\/10.1016\/j.exer.2007.05.008","journal-title":"Exp Eye Res"},{"key":"4957_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673","journal-title":"N Engl J Med"},{"key":"4957_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12886-018-0785-3","volume":"18","author":"CL Nguyen","year":"2018","unstructured":"Nguyen CL, Oh LJ, Wong E et al (2018) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol 18:130. https:\/\/doi.org\/10.1186\/s12886-018-0785-3","journal-title":"BMC Ophthalmol"},{"key":"4957_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart MW (2012) Aflibercept (VEGF trap-eye): The newest anti-VEGF drug. Br J Ophthalmol 96:1157\u20131158","journal-title":"Br J Ophthalmol"},{"key":"4957_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"4957_CR8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119:1621\u20131627. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.022","journal-title":"Ophthalmology"},{"key":"4957_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","volume":"254","author":"C Yun","year":"2016","unstructured":"Yun C, Oh J, Ahn J et al (2016) Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 254:1693\u20131702. https:\/\/doi.org\/10.1007\/s00417-015-3260-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4957_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/jop.2014.0160","volume":"31","author":"M Gharbiya","year":"2015","unstructured":"Gharbiya M, Cruciani F, Mariotti C et al (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357\u2013362. https:\/\/doi.org\/10.1089\/jop.2014.0160","journal-title":"J Ocul Pharmacol Ther"},{"key":"4957_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A et al (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159:627\u2013633.e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.12.025","journal-title":"Am J Ophthalmol"},{"key":"4957_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A et al (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration twelve-month results. Ophthalmology 123:617\u2013624. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.039","journal-title":"Ophthalmology"},{"key":"4957_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/IAE.0000000000000354","volume":"35","author":"H Kim","year":"2015","unstructured":"Kim H, Lee K, Lee CS et al (2015) Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Retina 35:481\u2013486. https:\/\/doi.org\/10.1097\/IAE.0000000000000354","journal-title":"Retina"},{"key":"4957_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/OPTH.S30907","volume":"6","author":"AA Ellabban","year":"2012","unstructured":"Ellabban AA, Tsujikawa A, Ogino K et al (2012) Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6:837\u2013844. https:\/\/doi.org\/10.2147\/OPTH.S30907","journal-title":"Clin Ophthalmol"},{"key":"4957_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40259-016-0179-0","volume":"30","author":"AM Minnella","year":"2016","unstructured":"Minnella AM, Federici M, Falsini B et al (2016) Choroidal thickness changes after intravitreal ranibizumab for exudative age-related macular degeneration. BioDrugs 30:353\u2013359. https:\/\/doi.org\/10.1007\/s40259-016-0179-0","journal-title":"BioDrugs"},{"key":"4957_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ajo.2014.10.034","volume":"159","author":"P Gupta","year":"2015","unstructured":"Gupta P, Jing T, Marziliano P et al (2015) Distribution and determinants of choroidal thickness and volume using automated segmentation software in a population-based study. Am J Ophthalmol 159:293\u2013301.e3. https:\/\/doi.org\/10.1016\/j.ajo.2014.10.034","journal-title":"Am J Ophthalmol"},{"key":"4957_CR17","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1111\/aos.12794","volume":"94","author":"LT Sansom","year":"2016","unstructured":"Sansom LT, Suter CA, McKibbin M (2016) The association between systolic blood pressure, ocular perfusion pressure and subfoveal choroidal thickness in normal individuals. Acta Ophthalmol 94:e157\u2013e158","journal-title":"Acta Ophthalmol"},{"key":"4957_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ajo.2015.03.005","volume":"159","author":"S Sonoda","year":"2015","unstructured":"Sonoda S, Sakamoto T, Yamashita T et al (2015) Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol 159:1123\u20131131.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.03.005","journal-title":"Am J Ophthalmol"},{"key":"4957_CR19","doi-asserted-by":"publisher","unstructured":"Agrawal R, Gupta P, Tan KA et al (2016) Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep 6. https:\/\/doi.org\/10.1038\/srep21090","DOI":"10.1038\/srep21090"},{"key":"4957_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2019.03.028","volume":"205","author":"M Pellegrini","year":"2019","unstructured":"Pellegrini M, Giannaccare G, Bernabei F et al (2019) Choroidal vascular changes in arteritic and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 205:43\u201349. https:\/\/doi.org\/10.1016\/j.ajo.2019.03.028","journal-title":"Am J Ophthalmol"},{"key":"4957_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/jcm9020595","volume":"9","author":"C Iovino","year":"2020","unstructured":"Iovino C, Pellegrini M, Bernabei F et al (2020) Choroidal vascularity index: an in-depth analysis of this novel optical coherence tomography parameter. J Clin Med 9:595. https:\/\/doi.org\/10.3390\/jcm9020595","journal-title":"J Clin Med"},{"key":"4957_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/IAE.0000000000000482","volume":"35","author":"CM Gemmy Cheung","year":"2015","unstructured":"Gemmy Cheung CM, Laude A, Wong W et al (2015) Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified EVEREST criteria. Retina 35:1375\u20131380. https:\/\/doi.org\/10.1097\/IAE.0000000000000482","journal-title":"Retina"},{"key":"4957_CR23","doi-asserted-by":"publisher","unstructured":"Pellegrini M, Veronese C, Bernabei F et al (2019) Choroidal vascular changes in multiple evanescent white dot syndrome. Ocul Immunol Inflamm. https:\/\/doi.org\/10.1080\/09273948.2019.1678650","DOI":"10.1080\/09273948.2019.1678650"},{"key":"4957_CR24","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1111\/aos.13399","volume":"95","author":"LHL Koh","year":"2017","unstructured":"Koh LHL, Agrawal R, Khandelwal N et al (2017) Choroidal vascular changes in age-related macular degeneration. Acta Ophthalmol 95:e597\u2013e601. https:\/\/doi.org\/10.1111\/aos.13399","journal-title":"Acta Ophthalmol"},{"key":"4957_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1167\/iovs.17-22144","volume":"59","author":"N Padr\u00f3n-P\u00e9rez","year":"2018","unstructured":"Padr\u00f3n-P\u00e9rez N, Arias L, Rubio M et al (2018) Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Investig Ophthalmol Vis Sci 59:1119\u20131124. https:\/\/doi.org\/10.1167\/iovs.17-22144","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4957_CR26","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1167\/iovs.18-23960","volume":"59","author":"A Invernizzi","year":"2018","unstructured":"Invernizzi A, Benatti E, Cozzi M et al (2018) Choroidal structural changes correlate with neovascular activity in neovascular age related macular degeneration. Investig Ophthalmol Vis Sci 59:3836\u20133841. https:\/\/doi.org\/10.1167\/iovs.18-23960","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4957_CR27","doi-asserted-by":"publisher","unstructured":"Kim YK, Park SJ, Woo SJ, Park KH (2016) Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence. Retina 36:1516\u20131526. https:\/\/doi.org\/10.1097\/IAE.0000000000000952","DOI":"10.1097\/IAE.0000000000000952"},{"key":"4957_CR28","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1111\/aos.13763","volume":"96","author":"B Mottet","year":"2018","unstructured":"Mottet B, Aptel F, Geiser MH et al (2018) Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients. Acta Ophthalmol 96:e783\u2013e788. https:\/\/doi.org\/10.1111\/aos.13763","journal-title":"Acta Ophthalmol"},{"key":"4957_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","volume":"164","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Ng WY, Ng SR et al (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128\u2013136.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.024","journal-title":"Am J Ophthalmol"},{"key":"4957_CR30","doi-asserted-by":"publisher","unstructured":"Sonoda S, Sakamoto T, Otsuka H et al (2013) Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC Ophthalmol 13. https:\/\/doi.org\/10.1186\/1471-2415-13-43","DOI":"10.1186\/1471-2415-13-43"},{"key":"4957_CR31","first-page":"689","volume":"40","author":"RG Tilton","year":"1999","unstructured":"Tilton RG, Chang KC, Lejeune WS et al (1999) Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Investig Ophthalmol Vis Sci 40:689\u2013696","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4957_CR32","doi-asserted-by":"publisher","unstructured":"Peters S, Heiduschka P, Julien S et al (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143. https:\/\/doi.org\/10.1016\/j.ajo.2007.03.007","DOI":"10.1016\/j.ajo.2007.03.007"},{"key":"4957_CR33","doi-asserted-by":"publisher","first-page":"e770","DOI":"10.1111\/aos.13442","volume":"95","author":"R Agrawal","year":"2017","unstructured":"Agrawal R, Wei X, Goud A, Vupparaboina KK, Jana S, Chhablani J (2017) Influence of scanning area on choroidal vascularity index measurement using optical coherence tomography. Acta Ophthalmol 95:e770\u2013e775. https:\/\/doi.org\/10.1111\/aos.13442","journal-title":"Acta Ophthalmol"},{"key":"4957_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ajo.2008.12.008","volume":"147","author":"R Margolis","year":"2009","unstructured":"Margolis R, Spaide RF (2009) A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 147:811\u2013815. https:\/\/doi.org\/10.1016\/j.ajo.2008.12.008","journal-title":"Am J Ophthalmol"},{"key":"4957_CR35","doi-asserted-by":"publisher","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E et al (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 106:18751\u201318756. https:\/\/doi.org\/10.1073\/pnas.0905010106","DOI":"10.1073\/pnas.0905010106"},{"key":"4957_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1167\/iovs.18-24522","volume":"60","author":"T Hikichi","year":"2019","unstructured":"Hikichi T, Agarie M (2019) Reduced vessel density of the choriocapillaris during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci 60:1088\u20131095. https:\/\/doi.org\/10.1167\/iovs.18-24522","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4957_CR37","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A et al (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757\u2013e764. https:\/\/doi.org\/10.1111\/aos.13157","journal-title":"Acta Ophthalmol"},{"key":"4957_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/IAE.0000000000002459","volume":"40","author":"G Giannaccare","year":"2020","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S et al (2020) Choroidal vascularity index quantification in geographic atrophy using binarization of enhanced-depth imaging optical coherence tomographic scans. Retina 40:960\u2013965. https:\/\/doi.org\/10.1097\/IAE.0000000000002459","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04957-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T10:38:34Z","timestamp":1634121514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4957"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04957-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee \u201cSezione Area Centro, Regione Calabria\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All listed authors have provided consent for publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}